Hepion Pharmaceuticals ( (HEPA) ) has released a notification of late filing.
Hepion Pharmaceuticals, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the ongoing process of compiling necessary information, which could not be completed without unreasonable effort and expense. The company anticipates filing the report within a 15-day extension period. Financially, Hepion Pharmaceuticals expects significant changes in its results, notably a decrease in research and development expenses by $23.5 million, primarily due to reduced clinical trial costs and headcount. General and administrative expenses also decreased by $2.4 million. The notification was signed by John Brancaccio, the Interim Chief Executive Officer, who assured ongoing compliance efforts.
More about Hepion Pharmaceuticals
YTD Price Performance: -98.17%
Average Trading Volume: 1,118,239
Technical Sentiment Signal: Strong Buy
Current Market Cap: $518.4K
For a thorough assessment of HEPA stock, go to TipRanks’ Stock Analysis page.